|Bid||183.00 x 100|
|Ask||189.20 x 300|
|Day's Range||187.60 - 189.72|
|52 Week Range||150.38 - 191.10|
|PE Ratio (TTM)||17.10|
|Forward Dividend & Yield||5.28 (2.79%)|
|1y Target Est||N/A|
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal.
How Is Amgen Positioned for 2018? In January 2018, the FDA approved Amgen’s (AMGN) supplemental Biologics License Application (or sBLA) for Xgeva. Xgeva is used for the prevention of skeletal-related events in individuals with bone metastasis from solid tumors.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Johnson Research Group’s pick for the contest is the SPDR S&P Biotech (ETF) (NYSEARCA:XBI). 2018 has gotten off to a roaring start, and biotechnology stocks are no exception.